OpenURL Connection Search

Select item for more details and to access through your institution.

REAL‐WORLD OUTCOMES WITH NOVEL THERAPIES IN R/R DLBCL.
Published in:
Hematological Oncology, 2023, v. 41, p. 719, doi. 10.1002/hon.3165_573
By:
- Crombie, J.;
- Jun, M.;
- Wang, T.;
- Mutebi, A.;
- Wang, A.;
- Chibber, A.;
- Kamalakar, R.;
- Ukropec, J.;
- Blaedel, J.;
- Kalsekar, A.
Publication type:
Article
Efficacy of Subcutaneous Epcoritamab versus Axi‐cel in R/R DLBCL CAR T‐Naive and CAR T‐eligible patients: An Indirect Comparison.
Published in:
Hematological Oncology, 2023, v. 41, p. 453, doi. 10.1002/hon.3164_334
By:
- Thieblemont, C.;
- Fox, C. P.;
- Wang, A.;
- Sail, K.;
- Alshreef, A.;
- Moran, M.;
- Mutebi, A.;
- Blaedel, J.;
- Chirikov, V.;
- Salles, G.
Publication type:
Article
Real‐world treatment patterns and clinical outcomes among follicular lymphoma patients in the SEER‐Medicare population.
Published in:
Hematological Oncology, 2023, v. 41, p. 372, doi. 10.1002/hon.3164_269
By:
- Chihara, D.;
- Yang, S.;
- Chawla, S. Bains;
- Zhang, G.;
- Wang, A.;
- Yu, J.;
- Arnette, D.;
- Navarro, F. Rivas;
- Blaedel, J.;
- Mutebi, A.
Publication type:
Article
PRECLINICAL EVALUATION OF EPCORITAMAB COMBINED WITH STANDARD OF CARE AGENTS FOR THE TREATMENT OF B‐CELL LYMPHOMAS.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.78_2881
By:
- Chiu, C. W.;
- Hiemstra, I. H.;
- ten Hagen, W.;
- Snijdewint‐Nkairi, R.;
- de Jong, B.;
- Garrido Castro, P.;
- Kweekel, C.;
- Oliveri, R. S.;
- Elliot, B.;
- Wielgos‐Bonvallet, M.;
- Szafer‐Glusman, E.;
- Schuurhuis, D.;
- Blaedel, J.;
- Ahmadi, T.;
- Breij, E.;
- Sasser, A.K.;
- Jure‐Kunkel, M.
Publication type:
Article

Found: 4

REAL‐WORLD OUTCOMES WITH NOVEL THERAPIES IN R/R DLBCL.

Efficacy of Subcutaneous Epcoritamab versus Axi‐cel in R/R DLBCL CAR T‐Naive and CAR T‐eligible patients: An Indirect Comparison.

Real‐world treatment patterns and clinical outcomes among follicular lymphoma patients in the SEER‐Medicare population.

PRECLINICAL EVALUATION OF EPCORITAMAB COMBINED WITH STANDARD OF CARE AGENTS FOR THE TREATMENT OF B‐CELL LYMPHOMAS.